DALLAS, July 08, 2020 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented company focused on manufacturing and marketing aerosol delivery systems based on pressurized Metered Dose Inhaler (MDI) technology, announced today that it has delivered an initial 2,000 units under its previously announced 100,000 unit order.
Rapid Therapeutic Science Laboratories, Inc. Chairman and CEO, Donal R. Schmidt, Jr. stated, “RTSL is moving forward on its first major wholesale contract. We have completed the first shipment totaling 2,000 units of our proprietary CBD/CBG formula under our white label order of 100,000 units we previously announced. These MDIs are currently being sold through doctors’ offices and in pharmacies across the United States. The initial lot of 2,000 was presold by our customer before we manufactured them. We will continue to manufacture and ship under this order as we discuss additional white label opportunities with other distributors. This first shipment demonstrates our ability to deliver large unit orders on a timely basis while preserving product quality.”
News 
Market Data 
Discover 
